BEGIN:VCALENDAR VERSION:2.0 PRODID:-//Paradigms Foundation - ECPv6.18.2//NONSGML v1.0//EN CALSCALE:GREGORIAN METHOD:PUBLISH X-ORIGINAL-URL:https://paradigms.foundation X-WR-CALDESC:Events for Paradigms Foundation REFRESH-INTERVAL;VALUE=DURATION:PT1H X-Robots-Tag:noindex X-PUBLISHED-TTL:PT1H BEGIN:VTIMEZONE TZID:Europe/Paris BEGIN:DAYLIGHT TZOFFSETFROM:+0100 TZOFFSETTO:+0200 TZNAME:CEST DTSTART:20240331T010000 END:DAYLIGHT BEGIN:STANDARD TZOFFSETFROM:+0200 TZOFFSETTO:+0100 TZNAME:CET DTSTART:20241027T010000 END:STANDARD BEGIN:DAYLIGHT TZOFFSETFROM:+0100 TZOFFSETTO:+0200 TZNAME:CEST DTSTART:20250330T010000 END:DAYLIGHT BEGIN:STANDARD TZOFFSETFROM:+0200 TZOFFSETTO:+0100 TZNAME:CET DTSTART:20251026T010000 END:STANDARD BEGIN:DAYLIGHT TZOFFSETFROM:+0100 TZOFFSETTO:+0200 TZNAME:CEST DTSTART:20260329T010000 END:DAYLIGHT BEGIN:STANDARD TZOFFSETFROM:+0200 TZOFFSETTO:+0100 TZNAME:CET DTSTART:20261025T010000 END:STANDARD BEGIN:DAYLIGHT TZOFFSETFROM:+0100 TZOFFSETTO:+0200 TZNAME:CEST DTSTART:20270328T010000 END:DAYLIGHT BEGIN:STANDARD TZOFFSETFROM:+0200 TZOFFSETTO:+0100 TZNAME:CET DTSTART:20271031T010000 END:STANDARD END:VTIMEZONE BEGIN:VEVENT DTSTART;TZID=Europe/Paris:20250621T080000 DTEND;TZID=Europe/Paris:20250624T120000 DTSTAMP:20250617T083928Z CREATED:20250417T115722Z LAST-MODIFIED:20250617T083928Z UID:11637-1750492800-1750766400@paradigms.foundation SUMMARY:ParadigMS at EAN 2025 in Helsinki DESCRIPTION:We are excited to announce that ParadigMS will be present at the 11th European Academy of Neurology (EAN) Congress\, taking place from June 21 to 24\, 2025\, at the Messukeskus Expo and Convention Centre in Helsinki\, Finland .​ \n\n\n\nVisit us in the Neurohood\, booth #20\, a dedicated space within the congress designed for networking and collaboration among neurological organisations. At our booth\, you can explore our latest educational materials\, including peer-reviewed slide decks and EACCME® accredited E-learning programs\, all aimed at enhancing patient care in MS\, NMOSD\, and MOGAD.​ \n\n\n\nThe overarching theme of EAN 2025 is “Neurology within Society”\, focusing on the intersection of neurological practice and societal factors . This aligns with ParadigMS’ mission to bridge scientific research and clinical practice through high-quality medical education.​ \n\n\n\nFor more information about the EAN 2025 Congress\, including registration details and the full program\, please visit the official EAN website: \n\n\n\nWe look forward to connecting with you in Helsinki! \n\n\n\n\nEAN Website URL:https://paradigms.foundation/event/join-paradigms-at-ean-2025-in-helsinki/ ATTACH;FMTTYPE=image/jpeg:https://paradigms.foundation/wp-content/uploads/2025/04/LAU-PROD-banner-EAN-congress-2025-1080X655px-1.jpg END:VEVENT BEGIN:VEVENT DTSTART;TZID=Europe/Paris:20250905T160000 DTEND;TZID=Europe/Paris:20250905T203000 DTSTAMP:20250829T072821Z CREATED:20250702T093409Z LAST-MODIFIED:20250829T072821Z UID:12018-1757088000-1757104200@paradigms.foundation SUMMARY:Scientific Meeting: Continued medical education on translational neuro-immunology: Current and potential molecular targets for MS\, NMOSD and MOGAD therapies. DESCRIPTION:Join us in Athens on Friday\, 5th September 2025\, for an engaging scientific meeting that brings together leading minds in neuroimmunology. \n\n\n\nCo-organised by ParadigMS and the Hellenic Academy of Neuroimmunology\, this one-day programme will explore the latest translational insights into molecular targets for MS\, NMOSD\, and MOGAD therapies. \n\n\n\nFrom B-cells and astrocytes to the endocannabinoid and sphingosine systems\, internationally renowned experts will guide you through science and its clinical applications. \n\n\n\nWhether you’re a clinician or a researcher\, this is a unique opportunity to deepen your understanding\, exchange ideas\, and shape future treatment strategies—all in the historic setting of the University of Athens. \n\n\n\nPlease find and download the programme: \n\n\n\nParadigMS Scientific Meeting in Athens_ProgrammeDownload\n\n\n\nDownload the Scientific Meeting brochure\, including programme\, speakers\, sponsors. \n\n\n\nFinal ProgramDownload\n\n\n\nTo register – please click in the button below. You will be redirected into the registration platform: \n\n\n\n\nRegister\n\n\n\n\nThere is no registration fee. \n\n\n\n\n\n\n\n\n\nSpeakersSponsorsLocal secretariat\n\nAiras LauraProfessor of Neuroimmunology\, University of Turku\, Finland \n\n\n\nBakirtzis ChristosNeurologist\, 2nd Department of Neurology\, Aristotle University of Thessaloniki\, AHEPAUniversity Hospital of Thessaloniki\, Greece \n\n\n\nBoziki Marina-KleopatraAssistant Professor of Neurology\, AristotleUniversity of Thessaloniki\, Greece \n\n\n\nDeisenhammer FlorianProfessor of Neurology\, Medical Universityof Innsbruck\, Austria \n\n\n\nEvangelopoulos Eleftheria-MariaAssociate Professor of Neurology- Neurochemistry\, National and Kapodistrian University of Athens\, Greece \n\n\n\nGrigoriadis NikolaosProfessor of Neurology\, AristotleUniversity of Thessaloniki\, Head of the 2nd Department of Neurology\, AHEPAUniversity Hospital of Thessaloniki\, Greece \n\n\n\nHartung Hans-PeterProf. em. Dr.\, Department of Neurology\, Heinrich-Heine-University\, Düsseldorf\,Germany \n\n\n\nIliopoulos IoannisProfessor of Neurology\, University of Thrace\, Head of the Department of Neurology\, University of Thrace\, UniversityHospital of Alexandroupolis\, GreeceKontoulis Zinais Consultant Anaesthetist–Pain Medicine\,Athens\, Greece \n\n\n\nMagyari MelindaConsultant\, MD\, PhD\, Professor\, DanishMultiple Sclerosis Center\, The Danish Multiple Sclerosis Registry CopenhagenUniversity Hospital\, Rigshospitalet\, Denmark \n\n\n\n \n\n\n\nOreja-Guevara CeliaProfessor-Vice Chair of Neurology\, Head of Multiple Sclerosis Center\, UniversityHospital San Carlos Madrid\, Spain \n\n\n\nPozzilli CarloProfessor of Clinical Neuroscience\, University of Roma La Sapienza\, Italy \n\n\n\nProbert LesleyDirector of Research\, Head of the Department of Immunology\, Head of theLaboratory of Molecular Genetics\, Hellenic Pasteur Institute\, Athens\, Greece \n\n\n\nStathopoulos Panos-AlexiosAssistant Professor of Neurology and Neuroimmunology\, National andKapodistrian University of Athens\, Greece \n\n\n\nVan Wijmeersch BartAssociate Professor of Neurology\,University of Hasselt\, Belgium \n\n\n\nVermersch PatrickProfessor\, Vice-President of Research\, Head of the Departments of Neurology\,University of Lille\, France \n\n\n\nZakaria MagdProfessor of Neurology\, Ain Shams University Cairo\, President of the EgyptianMS\, Egyptian Society of Multiple Sclerosis\, Egypt \n\n\n\nZiemssen TjalfProfessor of Clinical Neuroscience\, Head of the Multiple Sclerosis Center andNeuroimmunological Laboratory\, Director of Division of Neurometabolism\, UniversityClinic Carl-Gustav Carus\, Dresden\, Germany \n\n\n\n\n\n\n\n\n\n\n\nwww.globalevents.grThessaloniki: 50 A Stadiou Str.\, 55534\, Pylaia\, ThessalonikiΤ +30 2310 247743\, Ε info@globalevents.grAthens: 2 Valestra str. & 168 A. Syngrou Av.\, 17671\, AthensΤ +30 210 3250260\, Ε athens@globalevents.gr URL:https://paradigms.foundation/event/scientific-meeting-continued-medical-education-on-translational-neuro-immunology-current-and-potential-molecular-targets-for-ms-nmosd-and-mogad-therapies/ LOCATION:Alkis Argyriadis Amphitheatre – National and Kapodistrian University of Athens\, Panepistimiou St. 30\, Athens\, Greece ATTACH;FMTTYPE=image/jpeg:https://paradigms.foundation/wp-content/uploads/2025/07/Banners_Linkedin--scaled.jpg END:VEVENT BEGIN:VEVENT DTSTART;TZID=Europe/Paris:20250906T080000 DTEND;TZID=Europe/Paris:20250906T140000 DTSTAMP:20250827T083547Z CREATED:20250710T130138Z LAST-MODIFIED:20250827T083547Z UID:12036-1757145600-1757167200@paradigms.foundation SUMMARY:ParadigMS Experts Meeting DESCRIPTION:On Saturday\,6th September\, ParadigMS will convene an Expert Meeting in Athens\, assembling top specialists in multiple sclerosis to review and discuss educational materials on MS treatment and care. \n\n\n\nThe participation is on invitation only. \n\n\n\nThe detailed agenda of the meeting you may find below: \n\n\n\n\n8:30 – 8:40 Welcome and introduction to the agenda\n\n\n\n8:40 – 8:45 Overview of presentations that will be published on the ParadigMS website \n\n\n\nSafety tests within the clinical management of multiple sclerosis \n\n\n\nB-Cell therapies in the treatment of multiple sclerosis \n\n\n\nDiagnosis and clinical management of NMOSD\n\n\n\n8:45 – 10:15 Presentations – Part I\n\n\n\nBody fluid markers \n\n\n\nUse of AI and technology in MS clinical care pathways \n\n\n\nReal life experiences with generics and biosimilars\n\n\n\nSymptomatic therapies in multiple sclerosis (Part I\, Spasticity\, Ataxia\, Mobility\, Tremor\, Pain\, Tingling)\n\n\n\n\n10:15 – 10:45 BREAK   \n\n\n\n\n10:45 – 11:45 Presentations – Part II\n\n\n\nSymptomatic therapies in multiple sclerosis (Part II\, Vertigo and dizziness\, Dysphagia\, Autonomic dysfunction\, Bladder and Bowel\, Sexual problems\, Fatigue\, Cognitive problems\, Emotional problems)\n\n\n\nBrain health in multiple sclerosis \n\n\n\n11:45 – 12:00 Articles – Status\n\n\n\nIn production: How to Uncover Subtle Progression in MS.\n\n\n\nPublished: Current state of knowledge on role of microglia in health and disease: implications for the management of MS\n\n\n\nPublished: Review paper: The use of generics and biosimilars in the treatment of multiple sclerosis\n\n\n\nProposed new topic for a paper: Diagnosis and clinical management of NMO/Optic Neuritis and MS\n\n\n\n12:00 – 12:20 Projects – Status\n\n\n\nProposal: Quality of care in MS: A comparative study of European quality indicators and implementation practices\n\n\n\nPrognosis in Multiple Sclerosis\n\n\n\n12:20 -13:00 E-learnings – status\n\n\n\nPublished: Beyond EDSS: How to Monitor Disease Progression in Multiple Sclerosis.\n\n\n\nOngoing: Beyond EDSS: How to Monitor Disease Progression in Multiple Sclerosis – instruction videos\n\n\n\n\n13:00 LUNCH \n\n\n\n \n\n\n\nMeeting Sponsors:\n\n\n\nThe ParadigMS Experts Meeting is sponsors by Sandoz and Sanofi. URL:https://paradigms.foundation/event/paradigms-expert-meeting/ ATTACH;FMTTYPE=image/png:https://paradigms.foundation/wp-content/uploads/2025/07/Activity-2.png END:VEVENT BEGIN:VEVENT DTSTART;TZID=Europe/Paris:20250924T080000 DTEND;TZID=Europe/Paris:20250926T170000 DTSTAMP:20250715T114939Z CREATED:20250714T140503Z LAST-MODIFIED:20250715T114939Z UID:12106-1758700800-1758906000@paradigms.foundation SUMMARY:ParadigMS presence at ECTRIMS 2025 DESCRIPTION:ParadigMS at ECTRIMS 2025 – See You in Barcelona!We’re excited to be present at the 41st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) from 24–26 September 2025 in Barcelona\, Spain. \n\n\n\nJoin us to explore the latest in MS education\, access our newest publications\, and connect with the experts driving our e-learning and clinical content. Whether you’re interested in diagnostic updates\, treatment strategies\, or translational research\, ParadigMS is here to support your learning journey. \n\n\n\n🧠 Visit our booth to discover how we’re advancing MS education—for neurologists\, by neurologists. URL:https://paradigms.foundation/event/paradigms-presence-at-ectrims-2025/ ATTACH;FMTTYPE=image/png:https://paradigms.foundation/wp-content/uploads/2025/07/Activity-3.png END:VEVENT BEGIN:VEVENT DTSTART;TZID=Europe/Paris:20251028T170000 DTEND;TZID=Europe/Paris:20251028T180000 DTSTAMP:20251111T104723Z CREATED:20251007T091908Z LAST-MODIFIED:20251111T104723Z UID:12322-1761670800-1761674400@paradigms.foundation SUMMARY:Live webinar on Real-Life Experiences with biosimilars DESCRIPTION:Live webinar on Real-Life Experiences with Biosimilars \n\n\n\nDuring this live webinar\, Prof. Tjalf Ziemssen and Prof. Jelena Drulovic\, MS and neuroimmunology experts\, will share their real-life experiences with biosimilars in multiple sclerosis clinical practice. \n\n\n\nJoin us for an insightful webinar exploring how biosimilars in multiple sclerosis (MS) are being integrated into clinical practice. Learn how biosimilars are used and how the switch is prepared from both a person with MS and physician perspective. \n\n\n\nWe’ll discuss: \n\n\n\n\nWhat biosimilars are and how regulatory agencies like the EMA and FDA ensure their safety and equivalence.\n\n\n\nPatient perspectives — addressing concerns about efficacy\, safety\, and the psychological impact of switching treatments.\n\n\n\nClinician challenges — balancing payer pressure\, communication with patients\, and the importance of transparency.\n\n\n\nSystem-level impact — how biosimilars can generate cost savings and expand treatment access.\n\n\n\nReal-world examples — case vignettes highlighting both successful transitions and the influence of the nocebo effect.\n\n\n\n\nDiscover the science\, the communication strategies\, and the real-world experiences driving the future of multiple sclerosis care. \n\n\n\nRegister to access the webinar\n\n\n\nThis session will be held live on Zoom. We warmly encourage you to register in advance to secure your place and take part in the exchange of knowledge and discussions. \n\n\n\n\nRegister here to join the live webinar\n\n\n\n\nLanguage\n\n\n\nThe session will be held in English with translated auto-captions into many languages\, offered by Zoom platform. \n\n\n\nThis webinar might interest you if you are: \n\n\n\n\nNeurologists with a particular interest in multiple sclerosis therapies and treatments\n\n\n\nNeurologists in training\n\n\n\nNurses engaged in the care of patients with multiple sclerosis\n\n\n\nPatient representatives\n\n\n\n\nQuestions and discussion\n\n\n\nIf there are specific questions you would like to see addressed during the session\, we encourage you to share them in advance at learning@paradigms.foundation. This will allow the speakers to incorporate them into their presentations. \n\n\n\nYou will also have the opportunity to raise questions directly and actively contribute to the discussion during the webinar and the dedicated Q&A session. \n\n\n\nTechnology used\n\n\n\nThe session will be conducted via Zoom\, with access credentials shared upon completion of your registration. \n\n\n\nTime and date\n\n\n\nThe session will be held in English on Tuesday\, 28th October 2025 from 17:00 to 18:00 CEST. \n\n\n\nParadigMS Speakers\n\n\n\n\n\n\n\nProfessor Tjalf Ziemssen\n\n\n\nProfessor of Clinical Neuroscience at University Clinic Carl-Gustav Carus in Dresden \n\n\n\n\n\n\n\nProfessor Jelena Drulovic\n\n\n\nProfessor of Neurology at the Faculty of Medicine\, University of Belgrade \n\n\n\nModerator\n\n\n\nStefaan de Corte\, ParadigMS General Manager \n\n\n\nRegistration\n\n\n\nRegistration is required and can be finalized either via the button located at the top of this page or through the following button below. \n\n\n\n\nRegistration\n\n\n\n\nFunding\n\n\n\nThis webinar is organised with the financial support of Sandoz. \n\n\n\nSandoz has not been involved in the elaboration of the presentations. URL:https://paradigms.foundation/event/live-webinar-on-real-life-experiences-with-biosimilars/ ATTACH;FMTTYPE=image/jpeg:https://paradigms.foundation/wp-content/uploads/2025/10/LAU-PROD-banner-live-webinar-sessions-251028-1080x655px-banner.jpg ORGANIZER;CN="ParadigMS":MAILTO:secretariat@paradigms.foundation END:VEVENT BEGIN:VEVENT DTSTART;TZID=Europe/Paris:20251106T130000 DTEND;TZID=Europe/Paris:20251106T200000 DTSTAMP:20251208T130443Z CREATED:20250616T152302Z LAST-MODIFIED:20251208T130443Z UID:11707-1762434000-1762459200@paradigms.foundation SUMMARY:ParadigMS Regional MS Symposium DESCRIPTION:The ParadigMS Regional MS Symposium in Belgrade\, co-organised by the Serbian Neuroimmunology Society and the ParadigMS Foundation\, was specifically designed to address the clinical and educational needs of the Balkan region. The programme offered a deep dive into current challenges and evolving concepts in multiple sclerosis (MS) care\, including newly proposed diagnostic criteria\, radiological markers (such as PRLs and the central vein sign)\, cerebrospinal fluid analysis\, and the role of aging in MS. \n\n\n\nAttendees engaged in high-level discussions on detecting disease progression\, emerging biomarkers\, and updated approaches to NMOSD management. The final session highlighted the practical implications of generics and biosimilars\, as well as innovative therapeutic strategies including B-cell and CAR-T therapies. \n\n\n\nWith a combination of expert presentations\, dynamic panel debates\, and Q&A sessions\, the symposium was designed to support neurologists in translating complex scientific developments into clinical practice. \n\n\n\n \n\n\n\nParadigMS after movie\n\n\n\nThe symposium brought together a strong regional community of 120 neurologists and experts\, and the active participation throughout the sessions made for rich exchanges and practical takeaways. We are grateful to all speakers and attendees for contributing to such a dynamic atmosphere. To relive some of the highlights moments from Belgrade’s ParadigMS Regional MS Symposium\, we invite you to watch the after movie below. \n\n\n\n\n\n\n\nScientific Programme\n\n\n\n \n\n\n\nParadigMS Regional MS Symposium_ParadigMS and Serbian NeuroImmuno Society_ProgrammeDownload\n\n\n\nThe upcoming MS Symposium in Belgrade promises a rich programme of scientific exchange and clinical insights. Visit the official website to explore the line-up of expert speakers and stay informed about the agenda\, themes\, and registration. \n\n\n\n\nFind out more URL:https://paradigms.foundation/event/paradigms-regional-ms-symposium/ ATTACH;FMTTYPE=image/png:https://paradigms.foundation/wp-content/uploads/2025/05/Regional-Symposium-Balkans.png END:VEVENT BEGIN:VEVENT DTSTART;TZID=Europe/Paris:20251204T020000 DTEND;TZID=Europe/Paris:20251204T030000 DTSTAMP:20251113T145712Z CREATED:20251113T143637Z LAST-MODIFIED:20251113T145712Z UID:12451-1764813600-1764817200@paradigms.foundation SUMMARY:ParadigMS in Dubai for the Pre-MENACTRIMS Symposium DESCRIPTION:ParadigMS is pleased to announce its participation in the upcoming MENACTRIMS Congress by organizing a Pre-MENACTRIMS Symposium\, taking place on Thursday\, 4th December in Dubai\, United Arab Emirates at the Intercontinental Hotel Festival City. \n\n\n\n\n\n\n\n\nVisit the ParadigMS pre-MENACTRIMS Symposium website\n\n\n\n\nFree Make sure to register for free access to the Pre-MENACTRIMS Symposium \n\n\n\n\n\n\n\nMeet and discuss with the ParadigMS team on Friday 5th and Saturday 6th December at the ParadigMS booth during MENACTRIMS Congress\, where attendees can discover our latest content\, including peer-reviewed slide decks\, accredited e-learning modules\, and expert-driven educational resources in MS\, NMOSD\, and MOGAD. \n\n\n\n\n\n\n\n\n\n\n\nWith thanks to our sponsor\, who supports this event without any involvement in the elaboration of the presentations. URL:https://paradigms.foundation/event/paradigms-in-dubai-for-the-pre-menactrims-symposium/ END:VEVENT BEGIN:VEVENT DTSTART;TZID=Europe/Paris:20251216T160000 DTEND;TZID=Europe/Paris:20251216T170000 DTSTAMP:20251127T133242Z CREATED:20251114T135924Z LAST-MODIFIED:20251127T133242Z UID:12467-1765900800-1765904400@paradigms.foundation SUMMARY:Live Webinar on MRI & diagnostic criteria DESCRIPTION:MRI & diagnostic criteria \n\n\n\nDuring this live webinar\, Prof. Cristina Granziera and Prof. Celia Oreja-Guevara\, MS and Neuroimmunology experts\, will share key insights on MRI and diagnostic criteria in multiple sclerosis clinical practice. \n\n\n\nJoin us for an interactive and up-to-date session exploring how MRI guides the diagnosis\, differential diagnosis and monitoring of Multiple Sclerosis (MS). Our speakers will walk you through the MRI features that matter most in clinical decision-making\, explaining how lesion characteristics support dissemination in space and time within the MS diagnostic framework. \n\n\n\nCelia Oreja-Guevara will also introduce the new diagnostic criteria\, highlighting what changes for clinicians and how MRI can facilitate earlier and more accurate diagnosis. \n\n\n\nThe webinar will further explore the prognostic value of MRI\, and participants will be introduced to advanced MRI techniques as well as emerging biomarkers. \n\n\n\nFinally\, the webinar will address MRI red flags and differential diagnosis\, helping clinicians distinguish MS from common mimics and avoid misdiagnosis . \n\n\n\nThis session brings together core principles\, new diagnostic perspectives\, and advanced imaging insights to support clinicians in making confident\, evidence-based decisions in MS care. \n\n\n\nThroughout the webinar\, participants will have the opportunity to ask questions directly to the experts\, ensuring a dynamic and clinically relevant discussion. \n\n\n\nKey Highlights\n\n\n\n\nExpert insights from two leading MS specialists\n\n\n\nPractical review of MRI markers essential for MS diagnosis\n\n\n\nOverview of the new diagnostic criteria and their impact on practice\n\n\n\nPrognostic MRI indicators linked to disability progression\n\n\n\nIntroduction to advanced techniques and new biomarkers\n\n\n\nMRI red flags and differential diagnosis strategies\n\n\n\nLive Q&A to address your clinical questions\n\n\n\n\nRegister to access the webinar\n\n\n\nThis session will be held live on Zoom. We warmly encourage you to register in advance to secure your place and take part in the exchange of knowledge and discussions. \n\n\n\n\nRegister here to join the live webinar\n\n\n\n\nLanguage\n\n\n\nThe session will be held in English with translated auto-captions into many languages\, offered by Zoom platform. \n\n\n\nThis webinar might interest you if you are: \n\n\n\n\nNeurologists with a particular interest in multiple sclerosis therapies and treatments\n\n\n\nNeurologists in training\n\n\n\nNurses engaged in the care of patients with multiple sclerosis\n\n\n\nPatient representatives\n\n\n\n\nQuestions and discussion\n\n\n\nIf there are specific questions you would like to see addressed during the session\, we encourage you to share them in advance at learning@paradigms.foundation. This will allow the speakers to incorporate them into their presentations. \n\n\n\nYou will also have the opportunity to raise questions directly and actively contribute to the discussion during the webinar and the dedicated Q&A session. \n\n\n\nTechnology used\n\n\n\nThe session will be conducted via Zoom\, with access credentials shared upon completion of your registration. \n\n\n\nTime and date\n\n\n\nThe session will be held in English on Tuesday\, 16th December 2025 from 16:00 to 17:00 CET. \n\n\n\nParadigMS Speakers\n\n\n\n\n\n\n\nProfessor Cristina Granziera \n\n\n\nCo-CEO of the Research Center for Clinical Neuroimmunology and Neuroscience Basel\, Professor at the University of Basel\, and senior consultant neurologist at the University Hospital of Basel  \n\n\n\n\n\n\n\n\n\n\n\nProfessor Celia Oreja-Guevara\n\n\n\nVice Chair of Neurology and Head of Multiple Sclerosis Center at the University Hospital San Carlos\, Madrid \n\n\n\nRegistration\n\n\n\nRegistration is required and can be finalized either via the button located at the top of this page or through the following button below. \n\n\n\n\nRegistration\n\n\n\n\nFunding\n\n\n\nThis webinar is funded with ParadigMS own funds. No other sponsors have been invited to support this webinar. URL:https://paradigms.foundation/event/live-webinar-on-mri-diagnostic-criteria/ ATTACH;FMTTYPE=image/jpeg:https://paradigms.foundation/wp-content/uploads/2025/11/LAU-PROD-banner-live-webinar-sessions-251216-1200x627px.jpg END:VEVENT BEGIN:VEVENT DTSTART;TZID=Europe/Paris:20260129T200000 DTEND;TZID=Europe/Paris:20260129T210000 DTSTAMP:20260120T094718Z CREATED:20251119T105946Z LAST-MODIFIED:20260120T094718Z UID:12496-1769716800-1769720400@paradigms.foundation SUMMARY:Live Webinar on the Clinical management of NMOSD in Belgium DESCRIPTION:Neuromyelitis optica spectrum disorder (NMOSD) is a rare but highly disabling autoimmune disease that predominantly affects the optic nerves and spinal cord. Delayed or missed diagnosis can have life-changing consequences\, but evolving diagnostic criteria and new targeted therapies are reshaping outcomes for people living with NMOSD. \n\n\n\nIn this webinar\, Professor Vincent van Pesch will discuss practical\, real-world approaches to diagnosing and managing NMOSD in Belgium\, from the first suspicious attack to long-term treatment decisions and patient follow-up. The webinar will be introduced and moderated by Doctor  Melissa Cambron. \n\n\n\nRISIV/INAMI Accreditation: The number 26002105 has been assigned to this activity. \n\n\n\nActivity status: Application submitted – Verification by the NHIF. \n\n\n\nKey Highlights\n\n\n\n\nA clear overview of how NMOSD is recognised and differentiated from other neurological conditions such as MS.\n\n\n\nAn introduction to how clinicians typically confirm the diagnosis in everyday practice.\n\n\n\nGeneral principles for managing acute attacks and supporting long-term care.\n\n\n\nHow patient needs\, treatment access\, and care pathways influence clinical decision-making in Belgium.\n\n\n\nPractical considerations for improving patient experience and long-term outcomes.\n\n\n\nLive Q&A to address your clinical questions\n\n\n\n\nRegister to access the webinar\n\n\n\nThis session will be held live on Zoom. We warmly encourage you to register in advance to secure your place and take part in the exchange of knowledge and discussions. \n\n\n\n\nRegister here to join the live webinar\n\n\n\n\nLanguage\n\n\n\nThe session will be held in English with translated auto-captions into many languages\, offered by Zoom platform. \n\n\n\nThis webinar might interest you if you are: \n\n\n\n\nNeurologists with a particular interest in multiple sclerosis therapies and treatments\n\n\n\nNeurologists in training\n\n\n\nNurses engaged in the care of patients with multiple sclerosis\n\n\n\nPatient representatives\n\n\n\n\nQuestions and discussion\n\n\n\nIf there are specific questions you would like to see addressed during the session\, we encourage you to share them in advance at learning@paradigms.foundation. This will allow the speakers to incorporate them into their presentations. \n\n\n\nYou will also have the opportunity to raise questions directly and actively contribute to the discussion during the webinar and the dedicated Q&A session. \n\n\n\nTechnology used\n\n\n\nThe session will be conducted via Zoom\, with access credentials shared upon completion of your registration. \n\n\n\nTime and date\n\n\n\nThe session will be held in English on Thursday\, 29th January 2026 from 20:00 to 21:00 CET. \n\n\n\nInvited Speaker\n\n\n\n\n\n\n\nProfessor Vincent van Pesch\n\n\n\nProfessor of Neurology and Associate Head of the Neurology department of the Cliniques Universitaires Saint-Luc \n\n\n\nDr Van Pesch obtained his medical degree in 1999 from Université Catholique de Louvain and then completed his PhD thesis in neuroimmunology in 2003. He served as neurology resident at Department of Neurology\, Saint-Luc Hospital and then progressed in positions from Adjunct Clinical Head to Associate Clinical Head and finally to Adjunct Chief of Neurology Department at Cliniques Universitaires Saint-Luc. He is also responsible for a number of other services within the same place such as coordination and supervision of the neurophysiology unit and supervision and teaching of electroencephalography and evoked potentials to neurology residents. \n\n\n\nAt Université Catholique de Louvain\, Dr Van Pesch is a Profssor of Neurology and is responsible for teaching neuroimmunology and cerebrospinal fluid/neurochemistry analysis as he is the Principal investigator at Neurochemistry Unit at UCL. \n\n\n\nDr Van Pesch also greatly contributes to scientific publications and has over 200 published papers in a number of renowned journals. He is also co-editor of Frontiers Neurology\, section of Multiple Sclerosis and neuroimmunology and section of Neuroepidemiology and also Co-editor of the Acta Neurologica Belgica. \n\n\n\n\n\n\n\nProfessor Melissa Cambron\n\n\n\nMD\, PhD\, neuroinflammatory specialist at AZ Sint-Jan Bruges \n\n\n\nMelissa Cambron\, MD\, PhD\, is a neuroinflammatory specialist at AZ Sint-Jan Bruges\, a position she has held since 2018\, and is affiliated with Ghent University. She completed her specialization and obtained her PhD at the Vrije Universiteit Brussel (VUB). Dr. Cambron further expanded her clinical and academic expertise through a one-year fellowship in neurology at CHRU Lille under the supervision of Professor Patrick Vermersch. Her clinical and research interests focus on neuroinflammatory and neuroimmunological disorders\, including neuromyelitis optica spectrum disorders. \n\n\n\nRegistration\n\n\n\nRegistration is required and can be finalized either via the button located at the top of this page or through the following button below. \n\n\n\n\nRegistration\n\n\n\n\nFunding\n\n\n\nThis webinar is organized with the financial support of Alexion. Alexion has not been involved in the elaboration of the presentations. URL:https://paradigms.foundation/event/live-webinar-on-the-clinical-management-of-nmosd-in-belgium/ ATTACH;FMTTYPE=image/jpeg:https://paradigms.foundation/wp-content/uploads/2025/11/LAU-PROD-banner-live-webinar-sessions-260129-1080x655px-02-1.jpg END:VEVENT BEGIN:VEVENT DTSTART;TZID=Europe/Paris:20260310T163000 DTEND;TZID=Europe/Paris:20260310T173000 DTSTAMP:20260605T115256Z CREATED:20260226T135458Z LAST-MODIFIED:20260605T115256Z UID:13431-1773160200-1773163800@paradigms.foundation SUMMARY:Live Webinar on Pregnancy and Lactation in Multiple Sclerosis DESCRIPTION:Pregnancy and lactation in multiple sclerosis (MS) remain critical and often complex phases in a woman’s disease journey. Questions around relapse risk\, treatment interruption\, breastfeeding safety\, and long-term outcomes require careful\, individualized decision-making. With evolving evidence and updated recommendations\, clinicians must balance disease control with maternal and infant safety. \n\n\n\nIn this live webinar\, Celia Oreja-Guevara and Melinda Magyari will discuss practical\, real-world approaches to managing MS before\, during\, and after pregnancy. \n\n\n\n \n\n\n\nKey Highlights\n\n\n\n\nA clear overview of relapse risk and disease activity during pregnancy and the postpartum period.\n\n\n\nGuidance on treatment planning before conception and strategies around treatment interruption or continuation.\n\n\n\nPractical considerations for improving patient experience and long-term outcomes.\n\n\n\nLive Q&A to address your clinical questions\n\n\n\n\nRegister to access the webinar\n\n\n\nThis session will be held live on Zoom. We warmly encourage you to register in advance to secure your place and take part in the exchange of knowledge and discussions. \n\n\n\n\nRegister here to join the live webinar\n\n\n\n\nLanguage\n\n\n\nThe session will be held in English with translated auto-captions into many languages\, offered by Zoom platform. \n\n\n\nThis webinar might interest you if you are: \n\n\n\n\nNeurologists with a particular interest in multiple sclerosis therapies and treatments\n\n\n\nNeurologists in training\n\n\n\nNurses engaged in the care of patients with multiple sclerosis\n\n\n\nPatient representatives\n\n\n\n\nQuestions and discussion\n\n\n\nIf there are specific questions you would like to see addressed during the session\, we encourage you to share them in advance at learning@paradigms.foundation. This will allow the speakers to incorporate them into their presentations. \n\n\n\nYou will also have the opportunity to raise questions directly and actively contribute to the discussion during the webinar and the dedicated Q&A session. \n\n\n\nTechnology used\n\n\n\nThe session will be conducted via Zoom\, with access credentials shared upon completion of your registration. \n\n\n\nTime and date\n\n\n\nThe session will be held in English on Tuesday\, 10th March 2026 from 16:30 to 17:30 CET. \n\n\n\nInvited Speakers\n\n\n\n\n\n\n\nCelia Oreja-Guevara\n\n\n\nVice Chair of Neurology and Head of Multiple Sclerosis Center at the University Hospital San Carlos\, Madrid \n\n\n\nAfter receiving her MD from the University Complutense\, Madrid\, Professor Oreja-Guevara completed a PhD in neuroimmunology at the Max-Planck-Institute for Neurobiology\, University of Munich\, Munich (Germany). She then went on to complete a residency in the Department of Neurology at the University of Bochum\, Bochum (Germany) and a postdoctoral fellowship in neuroimaging at the University Hospital San Raffaele\, Milan (Italy). She has also held posts at the University of Düsseldorf (Germany)\,Hospital de Fuenlabrada and at the University Hospital La Paz\, both in Madrid. \n\n\n\nProfessor Oreja-Guevara’s research interests centre on family planning\, menopause\, clinical and neuroimaging correlations in MS and the use of optical coherence tomography. As an investigator\, she has participated in a number of MS clinical trials and currently heads Paradigms\, an independent and non-profit international group of Multiple Sclerosis experts. Currently\, Professor Oreja-Guevara is an expert for the Spanish Medicines Agency and for the Scientific Advisory Group on Neurology of the European Medicines Agency. \n\n\n\n\n\n\n\nMelinda Magyari\n\n\n\nDirector of the Danish Multiple Sclerosis Registry and Consultant neurologist at department of Neurology\, Rigshospitalet\, Denmark \n\n\n\nHer major research area is in multiple sclerosis and other inflammatory disorders of the central nervous system with a special interest in the changing epidemiology and gender differences. Using nationwide population-based data sources her research addresses questions on comorbidities\, reproductive issues\, risk factors and socioeconomic consequences in multiple sclerosis. She is involved in pharmacoepidemiological studies investigating the effectiveness and long-term safety of disease modifying therapies. \n\n\n\nFunding\n\n\n\nThis webinar is organized with the financial support of Roche. Roche has not been involved in the elaboration of the presentations. URL:https://paradigms.foundation/event/live-webinar-on-pregnancy-and-lactation-in-multiple-sclerosis/ ATTACH;FMTTYPE=image/jpeg:https://paradigms.foundation/wp-content/uploads/2026/02/LAU-PROD-banner-live-webinar-sessions-260310-1200x627px.jpg END:VEVENT BEGIN:VEVENT DTSTART;TZID=Europe/Paris:20260429T173000 DTEND;TZID=Europe/Paris:20260429T183000 DTSTAMP:20260413T155125Z CREATED:20260413T084357Z LAST-MODIFIED:20260413T155125Z UID:13900-1777483800-1777487400@paradigms.foundation SUMMARY:Live Webinar on the long-term efficacy and safety of anti-CD20 therapies DESCRIPTION:Anti-CD20 therapies have become a central component in the management of Multiple Sclerosis (MS)\, with growing evidence supporting their sustained use. In this live webinar\, Celia Oreja-Guevara and Patrick Vermersch will review long-term efficacy and safety data\, translating current evidence into practical insights for neurologists involved in treatment decisions. \n\n\n\n \n\n\n\nKey Highlights\n\n\n\n\nReview long-term efficacy data of anti-CD20 therapies in Multiple Sclerosis (MS) \n\n\n\nAssess safety profiles with extended treatment exposure \n\n\n\nDiscuss risk–benefit considerations in long-term disease management \n\n\n\nExplore real-world evidence and its implications for clinical practice \n\n\n\nAddress monitoring strategies and patient selection over time \n\n\n\nGain expert perspectives on optimizing treatment decisions\n\n\n\n\nRegister to access the webinar\n\n\n\nThis session will be held live on Zoom. We warmly encourage you to register in advance to secure your place and take part in the exchange of knowledge and discussions. \n\n\n\n\nRegister to access the webinar\n\n\n\n\nLanguage\n\n\n\nThe session will be held in English with translated auto-captions into many languages\, offered by Zoom platform. \n\n\n\nThis webinar might interest you if you are:\n\n\n\n\nNeurologists with a particular interest in multiple sclerosis therapies and treatments\n\n\n\nNeurologists in training\n\n\n\nNurses engaged in the care of patients with multiple sclerosis\n\n\n\nPatient representatives\n\n\n\n\nQuestions and discussion\n\n\n\nIf there are specific questions you would like to see addressed during the session\, we encourage you to share them in advance at learning@paradigms.foundation. This will allow the speakers to incorporate them into their presentations. \n\n\n\nYou will also have the opportunity to raise questions directly and actively contribute to the discussion during the webinar and the dedicated Q&A session. \n\n\n\nTechnology used\n\n\n\nThe session will be conducted via Zoom\, with access credentials shared upon completion of your registration. \n\n\n\nTime and date\n\n\n\nThe session will be held in English on Wednesday\, 29 April 2026 from 5:30 to 6:30 p.m. CET. \n\n\n\nInvited Speakers\n\n\n\n\n\n\n\nCelia Oreja-Guevara\n\n\n\nVice Chair of Neurology and Head of Multiple Sclerosis Center at the University Hospital San Carlos\, Madrid \n\n\n\nAfter receiving her MD from the University Complutense\, Madrid\, Professor Oreja-Guevara completed a PhD in neuroimmunology at the Max-Planck-Institute for Neurobiology\, University of Munich\, Munich (Germany). She then went on to complete a residency in the Department of Neurology at the University of Bochum\, Bochum (Germany) and a postdoctoral fellowship in neuroimaging at the University Hospital San Raffaele\, Milan (Italy). She has also held posts at the University of Düsseldorf (Germany)\,Hospital de Fuenlabrada and at the University Hospital La Paz\, both in Madrid. \n\n\n\nProfessor Oreja-Guevara’s research interests centre on family planning\, menopause\, clinical and neuroimaging correlations in MS and the use of optical coherence tomography. As an investigator\, she has participated in a number of MS clinical trials and currently heads Paradigms\, an independent and non-profit international group of Multiple Sclerosis experts. Currently\, Professor Oreja-Guevara is an expert for the Spanish Medicines Agency and for the Scientific Advisory Group on Neurology of the European Medicines Agency. \n\n\n\n\n\n\n\nPatrick Vermersch\n\n\n\nVice-president of Research in the fields of Life and Health Sciences at the University of Lille \n\n\n\nPatrick Vermersch studied medicine at Lille University Hospital (France)\, where he graduated in Neurology. Between 1990 and 1994 he pursued his training in basic research fields\, mainly in cellular biology\, obtaining a PhD addressing biochemical abnormalities associated with Alzheimer’s and other neurodegenerative diseases. He also conducted research related to the characterization of post-transcriptional anomalies of tau proteins. His research interests then turned to multiple sclerosis (MS). \n\n\n\nProf. Patrick Vermersch is head of one of the University of Lille’s departments of Neurology which deals with MS and other neuroinflammatory diseases. The department is primarily concerned with neuroimmunology and markers of disease evolution. \n\n\n\nProf. Patrick Vermersch is currently vice-president of research in the fields of Life and Health Sciences at the University of Lille. In 2000\, he and colleagues created the first MS network in northern France to improve MS care and research. His current areas of interest are prognostic markers in MS and neuroimmunology in general. He participates in many treatment protocols for MS. He has authored or co-authored approximately 380 scientific papers. His H-index (Web of Science) is 54. \n\n\n\nFunding\n\n\n\nThis webinar is organized with the financial support of Neuraxpharm. \n\n\n\nNeuraxpharm has not been involved in the elaboration of the presentations. URL:https://paradigms.foundation/event/live-webinar-on-the-long-term-efficacy-and-safety-of-anti-cd20-therapies/ ATTACH;FMTTYPE=image/jpeg:https://paradigms.foundation/wp-content/uploads/2026/04/LAU-PROD-banner-live-webinar-sessions-260429-1200x627px.jpg END:VEVENT BEGIN:VEVENT DTSTART;TZID=Europe/Paris:20260527T173000 DTEND;TZID=Europe/Paris:20260527T183000 DTSTAMP:20261013T152832Z CREATED:20260513T082653Z LAST-MODIFIED:20261013T152832Z UID:14311-1779903000-1779906600@paradigms.foundation SUMMARY:Live Webinar on the Early intervention in Multiple Sclerosis: the role of high-efficacy therapies in long-terms outcomes DESCRIPTION:Join ParadigMS Foundation for a live webinar exploring the evolving role of early intervention and high-efficacy therapies in Multiple Sclerosis (MS). This webinar will review current evidence on long-term clinical outcomes\, treatment strategies\, and practical considerations for neurologists involved in MS care. \n\n\n\nKey Highlights\n\n\n\n\nReview of current evidence on high-efficacy therapies and long-term outcomes \n\n\n\nPractical insights into treatment selection and therapeutic sequencing \n\n\n\nClinical perspectives from internationally recognized MS experts \n\n\n\nInteractive session designed for neurologists and MS healthcare professionals \n\n\n\nLive webinar with automated translation available for international participants \n\n\n\nOpportunity to explore evolving approaches to long-term MS management\n\n\n\n\nRegister to access the webinar\n\n\n\nThis session will be held live on Zoom. We warmly encourage you to register in advance to secure your place and take part in the exchange of knowledge and discussions. \n\n\n\n\nRegister to access the webinar\n\n\n\n\nLanguage\n\n\n\nThe session will be held in English with translated auto-captions into many languages\, offered by Zoom platform. \n\n\n\nThis webinar might interest you if you are:\n\n\n\n\nNeurologists with a particular interest in multiple sclerosis therapies and treatments\n\n\n\nNeurologists in training\n\n\n\nNurses engaged in the care of patients with multiple sclerosis\n\n\n\nPatient representatives\n\n\n\n\nQuestions and discussion\n\n\n\nIf there are specific questions you would like to see addressed during the session\, we encourage you to share them in advance at learning@paradigms.foundation. This will allow the speakers to incorporate them into their presentations. \n\n\n\nYou will also have the opportunity to raise questions directly and actively contribute to the discussion during the webinar and the dedicated Q&A session. \n\n\n\nTechnology used\n\n\n\nThe session will be conducted via Zoom\, with access credentials shared upon completion of your registration. \n\n\n\nTime and date\n\n\n\nThe session will be held in English on Wednesday\, 27 May 2026 from 5:30 to 6:30 p.m. CEST. \n\n\n\nInvited Speakers\n\n\n\n\n\n\n\nTjalf Ziemssen\n\n\n\nProfessor of Clinical Neuroscience at University Clinic Carl-Gustav Carus in Dresden  \n\n\n\n\n\n\n\nBart Van Wijmeersch\n\n\n\nAssociate Professor of Neurology at the University of Hasselt  \n\n\n\nFunding\n\n\n\nThis webinar is organized with the financial support of Sandoz. \n\n\n\nSandoz has not been involved in the elaboration of the presentations. URL:https://paradigms.foundation/event/live-webinar-on-the-early-intervention-in-multiple-sclerosis-the-role-of-high-efficacy-therapies-in-long-terms-outcomes/ ATTACH;FMTTYPE=image/jpeg:https://paradigms.foundation/wp-content/uploads/2026/05/LAU-PR3-1.jpg END:VEVENT BEGIN:VEVENT DTSTART;TZID=Europe/Paris:20260613T000000 DTEND;TZID=Europe/Paris:20260613T235959 DTSTAMP:20260616T140459Z CREATED:20251216T103224Z LAST-MODIFIED:20260616T140459Z UID:12647-1781308800-1781395199@paradigms.foundation SUMMARY:Annual MS Meeting 2026 DESCRIPTION:Saturday\, June 13th – morning session\n\n\n\n\n\n\n\nOptic Neuritis Unveiled: Clinical and Imaging Perspectives\n\n\n\nIrish College\, Leuven\n\n\n\nThe Belgian Study Group for Multiple Sclerosis (BSGMS) and ParadigMS Foundation are pleased to announce the Annual MS Meeting 2026\, a scientific meeting for the Belgian MS community and allied healthcare professionals. \n\n\n\nThis year’s meeting\, entitled “Optic Neuritis Unveiled: Clinical and Imaging Perspectives\,” will focus on optic neuritis as a key clinical entity in multiple sclerosis and related disorders. The programme will combine clinical expertise with advanced imaging approaches\, highlighting how evolving diagnostic tools can support earlier diagnosis\, improved prognostication\, and optimized patient management. \n\n\n\nPictures from the meeting (by DAVID PLAS PHOTOGRAPHY) \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nScientific Programme \n\n\n\nThe meeting will feature three keynote lectures delivered by internationally recognized experts\, followed by interactive case discussions and clinical conclusions. This is an in-person meeting and no livestream will be available. \n\n\n\n\n\n\n\n \n\n\n\nAbout the co-chairs and the keynotes speakers\n \n \n \n \n About the speakers\n \n \n \n About the co-Chairs\n \n \n \n \n \n\n\n\n\n\n\n\nAxel Petzold (UK) is a consultant neurologist at the National Hospital for Neurology and Neurosurgery\, Queen Square\, and at Moorfields Eye Hospital in London. His clinical and research work focuses on multiple sclerosis and optic neuritis. He is a Fellow of the Royal College of Physicians\, the Royal College of Ophthalmologists\, and the Royal College of Pathologists. Over the years\, he has been involved in a number of collaborative initiatives\, including serving as Chair for Neuro-Ophthalmology within the European Reference Networks for Rare Diseases. He has also helped develop integrated care pathways between his NHS Hospital Trusts. Prof Petzold has published widely in peer-reviewed journals and has supervised and mentored fellows and students from different countries. He remains committed to careful clinical practice\, collaborative research\, and supporting the next generation of clinicians and scientists. \n\n\n\n\n\n\n\n\n\nAnne-Catherine Chapelle (Belgium) is a neuro-ophthalmologist and pediatric ophthalmologist at the University Hospital of Liège\, where she is involved in both clinical practice and academic activities. She completed a neuro-ophthalmology fellowship in London under the supervision of Professor Gordon Plant\, gaining advanced expertise in the diagnosis and management of complex neuro-ophthalmic disorders\, including inflammatory and demyelinating diseases of the visual pathway. She subsequently completed a doctoral thesis focused on retinal ganglion cell evaluation in ischemic optic neuropathies\, with particular attention to structural and functional correlations. Her clinical and research interests center on optic nerve disorders and the use of retinal imaging\, notably optical coherence tomography (OCT)\, as a biomarker in neurological diseases. \n\n\n\n\n\n\n\n\n\n\n\n\n\nJette Lautrup Frederiksen (Denmark) is Professor of Neurology\, Senior Consultant\, MD and Doctor of Medical Sciences (DMSc) at University of Copenhagen based on thesis “A prospective Study of Acute Optic Neuritis: Clinical\, MRI. CSF\, Neurophysiological and HLA Findings”. She has 40 years of research experience in the clinical\, imaging\, neurophysiological and biomedical aspects of optic neuritis\, multiple sclerosis and neuro-ophthalmology. She is the founder of the Multiple Sclerosis Clinic at Copenhagen University Hospital Rigshospitalet Glostrup\, Denmark and head of the Optic Neuritis Clinic there. Since 2011 she has been Professor in Optic Neuritis in relation to Multiple Sclerosis at the University of Copenhagen. She is by Scholar GPS ranked No. 2 within the category Optic Neuritis lifelong and has authored more than 300 publications in international scientific journals. \n\n\n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\nBelgian Study Group for Multiple Sclerosis \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nParadigMS Foundation \n\n\n\n\n\n\nProf. Bénédicte Dubois (Belgium) is an internationally recognised neurologist and multiple sclerosis expert. She is Head of the Department of Neurology at University Hospitals Leuven\, Head of the Laboratory for Neuroimmunology\, and part-time Full Professor at the Faculty of Medicine of KU Leuven\, where she also leads the Research Group Experimental Neurology and oversees the medical clerkship centres. Alongside her leadership roles\, she is a pioneer of interdisciplinary MS care and precision medicine in Belgium\, and her translational research focuses on the neuroimmunological and genetic mechanisms underlying MS\, supported by a unique longitudinal patient database. She is also actively involved in multiple internal and external committees dedicated to education and scientific research. \n\n\n\nProf. Bart Van Wijmeersch (Belgium) is a neurologist specialised in multiple sclerosis and Associate Professor of Neurology at the University of Hasselt\, affiliated with the Biomedical Institute (BIOMED). He is Medical Director of the Rehabilitation and MS Center in Pelt\, where he leads a multidisciplinary MS team delivering comprehensive patient care. His academic and clinical work bridges immunological\, biomarker\, MRI\, electrophysiological\, and rehabilitation research in MS\, combining pre-clinical models\, clinical studies\, and translational approaches. In addition to his research and clinical leadership\, he plays an active educational role within the faculties of medicine and physiotherapy. He is a member of the Belgian Study Group of Multiple Sclerosis\, founding President of ParadigMS\, and serves on advisory boards for pharmaceutical companies active in MS research. In recognition of his scientific contributions\, he received an honorary award from the Flemish Government in 2019. \n\n\n\n \n\n\n\n \n \n \n \n\n\n\nAbstracts of the keynotes\nAxel Petzold (UK) – Clinical Aspects of Optic Neuritis \n\n\n\nOptic neuritis (ON) is an inflammatory disorder of the optic nerve and a common cause of visual loss\, particularly in young and middle-aged adults. Clinically\, ON presents with subacute unilateral visual loss\, periocular pain exacerbated by eye movement\, impaired colour vision\, and visual field defects. Although many patients recover high-contrast visual acuity\, residual deficits in contrast sensitivity\, colour perception\, visual fields\, and visual fatigue are common. Clinically a common cause in a Caucasian population is multiple sclerosis (MS). Some clinical features such as bilateral involvement\, severe visual loss\, poor recovery\, or absence of pain should prompt urgent evaluation for other ON subgroups. \n\n\n\nThe clinical spectrum of ON is heterogeneous. MS-associated ON (MS-ON) remains frequent in neurological practise. IN MS-ON visual recovery is typically good. In contrast\, aquaporin-4 antibody-associated ON (AQP4-ON) is typically more severe\, may be bilateral\, and carries a high risk of permanent visual disability and future relapses. Myelin oligodendrocyte glycoprotein antibody-associated ON (MOG-ON) often presents with marked optic disc swelling and exquisite corticosteroid responsiveness. The relapse risk in MOG-ON varies\, with about half of all cases being monophasic. Accurate early phenotyping of ON is therefore central to prognosis and long-term management. \n\n\n\nDiagnosis is clinical\, supported by magnetic resonance imaging (MRI)\, serum antibody testing (AQP4-IgG and MOG-IgG)\, and optical coherence tomography (OCT). Acute management commonly includes high-dose corticosteroids to accelerate recovery\, with escalation therapies such as plasma exchange or IVIG considered in severe or refractory cases. Secondary prevention strategies depend on aetiology and relapse risk\, particularly in antibody-mediated disease and in patients at high risk of developing MS. \n\n\n\nBeyond acute treatment\, clinical care must address visual rehabilitation\, mental health burden\, and relapse surveillance. Persistent pain\, visual fatigue\, and anxiety about recurrence are frequent but under-recognised sequelae. Despite advances in immunotherapy and diagnostics\, substantial global variability remains in access to timely imaging\, antibody testing\, specialist care\, and relapse-preventive therapy. \n\n\n\nON is therefore both a neurological emergency and a window into systemic inflammatory disease. Optimising clinical outcomes requires early recognition\, aetiology-driven management\, structured follow-up\, and equitable access to specialist services. \n\n\n\nAnne-Catherine Chapelle (Belgium) – Seeing Optic Neuritis Through Optical Coherence Tomography: a new biomarker \n\n\n\nSince the revised McDonald criteria now include the optic nerve as a fifth topographical location\, careful and precise neuro-ophthalmologic examination has become mandatory. Accurate diagnosis of optic neuritis relies on a comprehensive assessment\, including optical coherence tomography (OCT). This technique enables precise\, non-invasive quantification of the peripapillary retinal nerve fiber layer and the ganglion cell layer. In this keynote\, we will review the evidence linking OCT findings to the diagnosis of optic neuritis\, visual outcomes\, and disease activity\, as well as its role in monitoring disease evolution. These data highlight the growing relevance of OCT in both clinical practice and research. \n\n\n\nJette Latrup Frederiksen – Optic neuritis as a window to the brain: MRI and functional VEP \n\n\n\nThe 2024 revision of the McDonald criteria introduced a major change by including the optic nerve as the fifth anatomical location demonstrating dissemination in space (DIS)\, thereby enhancing the diagnostic sensitivity of MS. Not only MRI of the optic nerve\, but also VEP and OCT can confirm affection of the optic nerve. Thus structural as well as functional examinations of the visual pathways are important. This talk will mainly focus on imaging aspects (MRI of the optic nerve and brain) beyond OCT together with functional testing including VEP and multifocal VEP. \n\n\n\n\nVenue: The Irish College\, Leuven\, and Parking details \n \n \n \n \n Address of the venue\n \n \n \n About this Irish College\n \n \n \n About the parking\n \n \n \n \n \n\n\nLocation: Paridaensinstituut \n\n\n\nAddress : Janseniusstraat 1\, 3000 Leuven \n\n\n\nTelephone  : 016 31 04 30 \n\n\n\n\n\n \n\n\n\n\n\n\n\n\n\nThe Irish College Leuven was founded in 1607 and is one of the oldest Irish colleges on the European continent. It was established to educate Irish priests at a time when religious training was restricted in Ireland. Over the centuries\, the College became an important intellectual and cultural hub\, closely linked to the University of Leuven\, and played a key role in preserving Irish scholarship and heritage. Today\, it stands as a historical symbol of the long-standing academic and cultural ties between Ireland and Belgium. \n\n\n\n\n\nThe parking space is available near the venue. \n\n\n\nAccess & Parking \n\n\n\nBethlehem parking: \n\n\n\nFree parking is available at Bethlehem Parking\, Leuven. The address is Redingenstraat 21\, 3000 Leuven\, approximately a 5-minute walk from the venue.Access code is: 15953#. \n\n\n\nGroup parking: Q-Park Heilig Hart \n\n\n\nAddress : Naamsestraat 102\, 3000 Leuven (≈ 10-minute walk to Irish College) \n\n\n\n \n\n\n\n \n \n \n \n\n\n\nFAQ \n\nHow can I register for the event?\nSimply click on REGISTRATION button you can see above this section and then select your admission ticket category \n\n\n\n\nCan I bring a guest?\nAbsolutely! You can register up to 5 persons per session\, if they are also healthcare professionals with a focus on neurology \n\n\n\n\nHow can I get updates or notifications about the meeting?\nStay connected with all updates and news by subscribing to the ParadigMS Foundation webpage: https://paradigms.foundation/ \n\n\n\n\nWill there be food and beverages provided?\nYes\, we provide a welcome coffee\, a coffee break and a networking lunch with a variety of drinks. \n\n\n\n\nWhat if I need to cancel my registration?\nIf you need to cancel your registration\, please send a message to learning@paradigms.foundation. \n\n\n\n\nIs there a dress code for the meeting?\nWe recommend wearing smart casual attire. \n\n\n\n\nWill the Annual MS meeting be live streamed?\nNo\, the live sessions of the meeting are not live streamed and available only for onsite participants. \n\n\n\n\nWho can I contact for additional information?\nIf you have any questions or need further information about either of the two learning experiences\, please feel free to reach out to us at learning@paradigms.foundation. \n\n\n\n\nWill there be a written report from the sessions?\nYes\, the ParadigMS Secretariat is planning to have a medical writer on site who will be tasked with producing a written report from both sessions. \n\n\n\n\nWill any of the sessions be recorded on video for later viewing?\nYes\, the keynotes will be video and audio recorded and will be made available on ParadigMS.foundation. You will need to create a Member account to have access to the recording (conditions to join as a member apply). \n\n\n\n\n\n\nSponsorships\nIn return for their sponsorship\, our sponsors receive visibility and can register a limited number of their staff to join the Meeting. Sponsors are not involved in the elaboration of the programme and presentations.  \n\n\n\n \n \n \n \n Our gold sponsors\n \n \n \n Our bronze sponsors\n \n \n \n \n \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n\n \n \n \n \n\n\nInterested to join as a sponsor? Please contact ParadigMS at secretariat@paradigms.foundation \n\n\n\n\n \n\n\n\nOrganized by URL:https://paradigms.foundation/event/annual-ms-meeting-2026/ ATTACH;FMTTYPE=image/jpeg:https://paradigms.foundation/wp-content/uploads/2025/12/AMS2026-PROD-banner-1080x655px-01.jpg END:VEVENT BEGIN:VEVENT DTSTART;TZID=Europe/Paris:20260627T080000 DTEND;TZID=Europe/Paris:20260627T170000 DTSTAMP:20260511T075638Z CREATED:20260511T075637Z LAST-MODIFIED:20260511T075638Z UID:14295-1782547200-1782579600@paradigms.foundation SUMMARY:ParadigMS at EAN 2026 DESCRIPTION:We are excited to announce that ParadigMS will be present at the 12th Congress of the European Academy of Neurology (EAN) 2026\, taking place from June 27 to 30\, 2026\, at Palexpo in Geneva\, Switzerland. \n\n\n\nJoin us throughout the congress to discover the latest ParadigMS educational initiatives and resources dedicated to advancing care in Multiple Sclerosis (MS)\, Neuromyelitis Optica Spectrum Disorder (NMOSD)\, and MOG Antibody Disease (MOGAD). \n\n\n\nVisit our team in the Neurohood\, the dedicated networking and collaboration area for neurological organisations and partners. At our booth\, attendees will be able to explore: \n\n\n\n\nPeer-reviewed educational slide decks\n\n\n\nEACCME® accredited e-learning programmes\n\n\n\nScientific updates and practical clinical resources\n\n\n\nNew initiatives supporting multidisciplinary neurological care\n\n\n\n\nThe overarching theme of EAN 2026 is “Brains\, Bytes & Beyond: Tech in Neurology”\, highlighting how technological innovation and artificial intelligence are transforming neurological practice\, research\, and patient care. \n\n\n\nWe look forward to connecting with neurologists\, researchers\, healthcare professionals\, and partners from around the world in Geneva. \n\n\n\nFor more information about the congress\, visit: \n\n\n\n\nEAN Congress 2026 URL:https://paradigms.foundation/event/paradigms-at-ean-2026/ LOCATION:Palexpo Genova ATTACH;FMTTYPE=image/jpeg:https://paradigms.foundation/wp-content/uploads/2026/05/Congress-of-the-European-Academy-of-Neurology-EAN-2026-1.jpg END:VEVENT BEGIN:VEVENT DTSTART;TZID=Europe/Paris:20260904T140000 DTEND;TZID=Europe/Paris:20260904T180000 DTSTAMP:20260901T123003Z CREATED:20260603T145017Z LAST-MODIFIED:20260901T123003Z UID:14377-1788530400-1788544800@paradigms.foundation SUMMARY:Scientific meeting: Multiple Sclerosis - Multiple Predictors in Disease Prognostication DESCRIPTION:The scientific meeting chaired by ParadigMS expert Maura Pugliatti will be exploring current and emerging predictors of disease progression in Multiple Sclerosis.\n\n\n\nRegistration\n\n\n\nParticipation is free of charge\, but registration is required as places are limited. Please complete the registration form to confirm your attendance. \n\n\n\n\nRegister to attend the in-person scientific meeting\n\n\n\n\nMeeting details\n\n\n\nDate: Friday\, 4 September 2026Time: 13:00-18:10Location: Palazzo Roverella\, Ferrara\, ItalyRegistration: Free of chargeCME accreditation: No CME credits available \n\n\n\nUnderstanding disease progression remains one of the greatest challenges in Multiple Sclerosis (MS) care. This scientific meeting will bring together leading international experts to examine the diverse factors that contribute to disease prognostication\, from clinical and biological markers to emerging technologies and predictive models. \n\n\n\nParticipants will explore current evidence on pathophysiology\, biomarkers\, genetic studies\, registries\, comorbidities\, imaging\, and decision-support systems\, while discussing how these insights may support more personalized management strategies for people living with MS. \n\n\n\nDepliant_MS&NO_September4_DEFDownload\n\n\n\nDownload the programme \n\n\n\nScientific committee\n\n\n\n\nMaura Pugliatti\n\n\n\nCaterina Ferri\n\n\n\nNicola Merli\n\n\n\nMassimiliano Castellazzi\n\n\n\n\nProgramme overview\n\n\n\nSession I\n\n\n\nPrognostication in Multiple Sclerosis: Pathogenesis\, Pathophysiology and Clinical Presentation \n\n\n\n14:00Multiple sclerosis progression: pathophysiology and measurementsCelia Oreja-Guevara (Spain) \n\n\n\n14:20Clinical predictors of disease progressionBart Van Wijmeersch (Belgium) \n\n\n\n14:40Biomarkers in predicting multiple sclerosis worseningLaura Airas (Finland) \n\n\n\n15:00Prognostication from genetic studiesSandra D’Alfonso (Italy) \n\n\n\n15:20Investigating disease prognosis through data collection: the Italian MS RegistryPietro Iaffaldano (Italy) \n\n\n\n15:40Microchimerism in multiple sclerosisMichele Rubini (Italy) \n\n\n\n16:00Discussion \n\n\n\nSession II\n\n\n\nPrognostication in Multiple Sclerosis: Evidence About Less Conventional Predictors \n\n\n\n16:20Prognostication from cerebrospinal fluid analysisMassimiliano Castellazzi (Italy) \n\n\n\n16:40Comorbidities in multiple sclerosis progressionCaterina Ferri (Italy) \n\n\n\n17:00The role of ultrasound in prognosis through the study of the optic nerveNicola Merli (Italy) \n\n\n\nSession III\n\n\n\nPrognostication in Multiple Sclerosis: Moving Towards Algorithms and Decisional Support Systems \n\n\n\n17:20Decisional support systems\, modelling and algorithmsMassimiliano Copetti (Italy) \n\n\n\n17:40Prognostication in multiple sclerosis: the PROMISING StudyMaura Pugliatti (Italy) \n\n\n\n18:00Discussion \n\n\n\n18:10Closing remarksMaura Pugliatti (Italy) \n\n\n\nWhy attend?\n\n\n\nThis meeting offers a comprehensive overview of established and emerging predictors of disease progression in Multiple Sclerosis\, bringing together expertise from clinical practice\, epidemiology\, genetics\, biomarker research and data science. Attendees will gain practical insights into how prognostic tools may support more informed treatment decisions and personalised patient care. \n\n\n\nUnder the auspices of\n\n\n\n\nParadigMS\n\n\n\nUniversity of Ferrara\n\n\n\nFerrara University Hospital\n\n\n\nFerrara Health District\n\n\n\nItalian Society of Neurology (SIN)\n\n\n\nItalian Association of Neuroepidemiology (AINEP)\n\n\n\n\nSponsorships URL:https://paradigms.foundation/event/scientific-meeting-multiple-sclerosis-multiple-predictors-in-disease-prognostication/ ATTACH;FMTTYPE=image/jpeg:https://paradigms.foundation/wp-content/uploads/2026/06/Palazzo.jpg END:VEVENT BEGIN:VEVENT DTSTART;TZID=Europe/Paris:20260905T083000 DTEND;TZID=Europe/Paris:20260905T134500 DTSTAMP:20260605T090440Z CREATED:20260603T142911Z LAST-MODIFIED:20260605T090440Z UID:14355-1788597000-1788615900@paradigms.foundation SUMMARY:ParadigMS Expert Meeting 2026 DESCRIPTION:Casa d’Este – Hotel Ferrara\, Italy\n\n\n\n\n\nPractical details\n\n\n\nDate: Saturday\, 5 September 2026Time: 08:30 -13:45Location: Casa d’Este – Hotel Ferrara\, ItalyAudience: ParadigMS expert members \n\n\n\nUpon invitation meeting only \n\n\n\nThe ParadigMS Expert Meeting 2026 will bring together international neurologists and Multiple Sclerosis (MS) experts to discuss current and emerging topics in demyelinating diseases. \n\n\n\nThe programme will focus on new therapies\, paediatric MS\, symptomatic treatment\, healthcare system impact on treatment choice\, disability progression\, BTK inhibitors\, and clinical management of Neuromyelitis Optica Spectrum Disorder (NMOSD)\, optic neuritis and MS. \n\n\n\nProgramme overview\n\n\n\n08:30–08:45Introduction to the meetingCelia Oreja-Guevara \n\n\n\n08:45–09:15New therapies in MGAndrew Chan\, Maura Pugliatti \n\n\n\n09:15–09:45Paediatric MSMagd Zakaria\, Carlo Pozzilli \n\n\n\n09:45–10:15Symptomatic therapies in Multiple SclerosisVeronica Popescu\, Bart Van Wijmeersch\, Carlo Pozzilli\, Melinda Magyari\, Patrick Vermersch \n\n\n\n10:15–10:45Coffee break \n\n\n\n10:45–11:20How healthcare system classification impacts treatment choice in Multiple SclerosisThomas Berger\, Tjalf Ziemssen\, Nikolaos Grigoriadis\, Magd Zakaria\, Melinda Magyari \n\n\n\n11:20–11:40Prognosis in Multiple SclerosisMaura Pugliatti \n\n\n\n11:40–12:00Uncovering Disability Progression in People with Multiple Sclerosis: A Practical GuideBart Van Wijmeersch\, ParadigMS Office team \n\n\n\n12:00–12:40Treatment landscape and approaches in the era of BTK inhibitors \n\n\n\n12:40–13:10Lunch \n\n\n\n13:10–13:30Diagnosis and clinical management of NMO/Optic Neuritis and MSKazuo Fujihara\, Celia Oreja-Guevara\, Melinda Magyari \n\n\n\n13:30–13:45ClosingCelia Oreja-Guevara \n\n\n\n\n \n\n\n\n\nThe ParadigMS Expert Meeting will be sponsored by Roche\, Sandoz and Sanofi URL:https://paradigms.foundation/event/paradigms-expert-meeting-2026-ferrara-italy/ LOCATION:Ferrara\, Italy ATTACH;FMTTYPE=image/jpeg:https://paradigms.foundation/wp-content/uploads/2026/06/Castello-Estense.jpg END:VEVENT BEGIN:VEVENT DTSTART;TZID=Europe/Paris:20260929T163000 DTEND;TZID=Europe/Paris:20260929T173000 DTSTAMP:20260923T162319Z CREATED:20260901T100648Z LAST-MODIFIED:20260923T162319Z UID:14730-1790699400-1790703000@paradigms.foundation SUMMARY:Live Webinar on Paediatric Multiple Sclerosis DESCRIPTION:Join this ParadigMS live webinar dedicated to Paediatric Multiple Sclerosis (MS) and explore expert perspectives on the challenges of recognising\, diagnosing and managing MS in children and adolescents. \n\n\n\nThe session will bring together leading experts to discuss current clinical considerations and provide practical insights relevant to neurologists and healthcare professionals involved in MS care. \n\n\n\nKey Highlights\n\n\n\n\nEpidemiology\, genetic and environmental factors in paediatric MS.\n\n\n\nDisease course\, smouldering disease and risk of persistent disability.\n\n\n\nNew diagnostic criteria and differential diagnosis\, including NMOSD and MOGAD.\n\n\n\nCSF\, imaging and blood biomarkers.\n\n\n\nNeuropsychological performance\, quality of life and psychological issues.\n\n\n\nPharmacological therapies and evolving treatment approaches.\n\n\n\nLong-term monitoring and support for younger patients and their families.\n\n\n\nQ&A on key clinical challenges.\n\n\n\n\nMore information & Learning Objectives to come soon \n\n\n\nFind out more about the speakers: \n\n\n\nSpeakers\n\n\n\n\nThais Armangué \n\n\n\nCarlo Pozzilli\n\n\n\n\nModerator\n\n\n\n\nValeria Pozzilli\n\n\n\n\nRegister\n\n\n\nThis session will be delivered live on Zoom. Don’t miss this opportunity and register now to make sure you book your place and take part in knowledge exchange and discussions!  \n\n\n\n\nRegister for the live webinar\n\n\n\n\nLanguage\n\n\n\nThe session will be held in English with translated auto-captions into many languages (offered by Zoom platform). \n\n\n\nWhy participate?\n\n\n\n\nExplore the key clinical features of paediatric Multiple Sclerosis (MS)\n\n\n\nStrengthen diagnostic confidence in children and adolescents with suspected MS\n\n\n\nReview important differential diagnoses and challenges specific to paediatric-onset disease\n\n\n\nDiscuss current approaches to treatment selection and long-term disease management\n\n\n\nGain expert perspectives on monitoring disease activity and supporting care across the transition to adulthood\n\n\n\n\nWho should join?\n\n\n\n\nNeurologists and paediatric neurologists with an interest in Multiple Sclerosis\n\n\n\nMS specialists and neurologists in training\n\n\n\nNurses and other healthcare professionals involved in MS care\n\n\n\nHealthcare professionals involved in the diagnosis or management of paediatric demyelinating disorders\n\n\n\n\nQuestions and comments\n\n\n\nShould you have specific questions\, you would like to see discussed\, please share them with learning@paradigms.foundation now\, so the speakers could relate to them in their presentations.  \n\n\n\nYou will also have the opportunity to ask questions in person and participate in discussion during the webinar and the Q&A session. \n\n\n\nTechnology used\n\n\n\nThe webinar takes place via Zoom\, you will receive connection details upon registration. \n\n\n\nDate and time\n\n\n\nThe session will be held on Tuesday\, 29th September 2026 from 16:30 to 17:30 CEST. \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nCarlo Pozzilli\n\n\n\n\nProfessor of Clinical Neuroscience at University of Rome “La Sapienza” \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nThaìs Armangué\n\n\n\n\nHead of the Department and attending in the Paediatric Neuroimmunology Unit at SJD Barcelona Children’s Hospital \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nValeria Pozzilli\n\n\n\n\nNeurologist and researcher\, Queen Square MS Centre\, UCL Queen Square Institute of Neurology\, University College London\, United Kingdom \n\n\n\n\n\n\n\nRegistration\n\n\n\nRegistration is necessary and can be completed by clicking the button on top of this page or here: \n\n\n\n \n\n\n\n\nRegister now\n\n\n\n\nFunding\n\n\n\nThis webinar was organized with the financial support of Roche. \n\n\n\nRoche has not been involved in the elaboration of the presentations. URL:https://paradigms.foundation/event/live-webinar-on-paediatric-multiple-sclerosis/ ATTACH;FMTTYPE=image/jpeg:https://paradigms.foundation/wp-content/uploads/2026/09/PDMS-Live-webinar-banner-1080x655px_1.jpg END:VEVENT BEGIN:VEVENT DTSTART;TZID=Europe/Paris:20261029T170000 DTEND;TZID=Europe/Paris:20261029T180000 DTSTAMP:20261008T162216Z CREATED:20260714T120304Z LAST-MODIFIED:20261008T162216Z UID:14577-1793293200-1793296800@paradigms.foundation SUMMARY:Live Webinar on how healthcare system classification impacts treatment choice in multiple sclerosis DESCRIPTION:Healthcare systems play a fundamental role in determining how people living with Multiple Sclerosis (MS) access diagnosis\, treatment and long-term specialist care. While scientific advances continue to expand therapeutic options\, differences in healthcare organisation\, reimbursement policies\, drug availability and clinical pathways create substantial variation in patient care across countries. \n\n\n\nIn this expert panel discussion\, Thomas Berger will moderate a conversation with leading European neurologists and Paradigms members to explore how healthcare systems influence the delivery of optimal MS care. Through country-specific perspectives and interactive discussion\, the panel examines practical challenges\, identifies successful approaches\, and considers how healthcare systems can evolve to improve access to high-quality care while making efficient use of available resources. \n\n\n\n\nRegister for the live webinar\n\n\n\n\nLearning Objectives\n\n\n\nFollowing this webinar\, participants should be better able to: \n\n\n\n\nRecognize how differences in healthcare systems\, national guidelines and reimbursement policies can influence MS treatment choices and access to care.\n\n\n\nDiscuss the importance of balancing treatment costs with the broader clinical and societal burden of MS when considering healthcare resource allocation.\n\n\n\nExplore the role of neurologists\, multidisciplinary teams\, registries and real-world data in supporting evidence-based and integrated MS care.\n\n\n\nIdentify key considerations for sustainable access to high-quality MS treatments\, including treatment availability\, quality and continuity of supply.\n\n\n\nConsider opportunities to strengthen patient involvement in treatment decisions\, care delivery and data generation.\n\n\n\n\nWho should attend?\n\n\n\nThis webinar is intended for: \n\n\n\n\nClinically active neurologists\n\n\n\nMultiple Sclerosis specialists\n\n\n\nNeurology residents and trainees\n\n\n\nMS nurses and other healthcare professionals involved in multidisciplinary MS care\n\n\n\n\nThe webinar will be submitted for accreditation to the relevant Belgian authorities. \n\n\n\nRecording\n\n\n\nThe webinar recording is expected to be published on the ParadigMS educational platform following the live session. Access will be restricted to healthcare professionals. \n\n\n\nRegistration\n\n\n\nThis session will be delivered live on Zoom. Don’t miss this opportunity and register now to make sure you book your place and take part in knowledge exchange and discussions!  \n\n\n\n\nRegister for the live webinar\n\n\n\n\nLanguage\n\n\n\nThe session will be held in English with \n\n\n\nFind out more about the speakers: \n\n\n\nSpeakers\n\n\n\n\nThomas Berger (AT) (Moderator)\n\n\n\nMelinda Magyari (DK)\n\n\n\nNikolaos Grigoriadis (GR)\n\n\n\nJelena Drulovic (RS)\n\n\n\nMagd Zakaria (EG)\n\n\n\nTjalf Ziemssen (DE)\n\n\n\n\n\n\n\n\n\nThomas Berger\n\n\n\n\nProfessor of Neurology and Chair of the Dept. of Neurology at the Medical University of Vienna  \n\n\n\n\n\n\n\n\n\n\n\n\nMagd Zakaria\n\n\n\n\nHead of the Multiple Sclerosis Unit at the Ain Shams Specialized University Hospital  \n\n\n\n\n\n\n\n\n\n\n\n\nMelinda Magyari\n\n\n\n\nDirector of the Danish Multiple Sclerosis Registry \n\n\n\n\n\n\n\n\nTjalf Ziemssen\n\n\n\n\nProfessor of Clinical Neuroscience at University Clinic Carl-Gustav Carus in Dresden \n\n\n\n\n\n\n\n\n\n\n\n\nNikolaos Grigoriadis\n\n\n\n\nProfessor of Neurology at the Aristotle University of Thessaloniki \n\n\n\n\n\n\n\n\n\n\n\n\nJelena Drulovic\n\n\n\n\nProfessor of Neurology at the Faculty of Medicine\, University of Belgrade \n\n\n\n\n\n\n\nFunding \n\n\n\nThis webinar was organized with the financial support of Sandoz. \n\n\n\nSandoz has not been involved in the elaboration of the presentations. URL:https://paradigms.foundation/event/how-healthcare-system-classification-impacts-treatment-choice-in-multiple-sclerosis/ ATTACH;FMTTYPE=image/jpeg:https://paradigms.foundation/wp-content/uploads/2026/07/PMS-PROD-webinar-261029-banner-1080x655px.jpg END:VEVENT BEGIN:VEVENT DTSTART;TZID=Europe/Paris:20261123T170000 DTEND;TZID=Europe/Paris:20261123T181500 DTSTAMP:20261020T144017Z CREATED:20260804T090238Z LAST-MODIFIED:20261020T144017Z UID:14645-1795453200-1795457700@paradigms.foundation SUMMARY:Live Webinar: A Biosimilar in Multiple Sclerosis Care in Belgium: Evidence\, Confidence and Implementation DESCRIPTION:Live webinar | Online \n\n\n\nJoin a 75-minute expert-led webinar examining the clinical\, regulatory and practical considerations involved in introducing a biosimilar into Multiple Sclerosis (MS) care in Belgium. \n\n\n\nThe programme will combine Belgian healthcare perspectives with experience from France and practical insights into MS-centre workflows. Participants will also have the opportunity to discuss implementation questions during an extended panel discussion and Q&A. \n\n\n\n\nRegister for the live webinar\n\n\n\n\nAbout the webinar\n\n\n\nWith the expected introduction of a biosimilar treatment option in Belgian MS care\, neurologists need clear and independent education on how biosimilars are assessed\, approved and implemented. \n\n\n\nThis webinar will address the regulatory principles and clinical evidence supporting biosimilars\, including how they differ from generics. It will also consider how international experience may inform decision-making in Belgium. \n\n\n\nThe faculty will discuss practical implementation in daily MS care\, including communication with people living with MS\, shared decision-making\, infusion-centre pathways\, multidisciplinary coordination and monitoring procedures. \n\n\n\nLearning objectives\n\n\n\nBy the end of the webinar\, participants will be able to: \n\n\n\n\nExplain the regulatory framework for biosimilars and how biosimilars differ from generics.\n\n\n\nRelate experience from the introduction of a biosimilar in France to the Belgian context.\n\n\n\nDiscuss practical approaches to patient communication\, infusion pathways and monitoring when implementing biosimilars in MS care.\n\n\n\nSupport informed discussion about biosimilars with multidisciplinary care teams and people living with Multiple Sclerosis.\n\n\n\nConsider the practical implications of biosimilar implementation for MS-centre workflows.\n\n\n\n\nWho should attend?\n\n\n\nThis webinar is intended for: \n\n\n\n\nClinically active neurologists based in Belgium\n\n\n\nMultiple Sclerosis specialists\n\n\n\nNeurology residents and trainees\n\n\n\nMS nurses and other healthcare professionals involved in multidisciplinary MS care\n\n\n\n\nThe webinar will be submitted for accreditation to the relevant Belgian authorities. \n\n\n\nRecording\n\n\n\nThe webinar recording is expected to be published on the ParadigMS educational platform following the live session. Access will be restricted to healthcare professionals. \n\n\n\nRegistration\n\n\n\nThis session will be delivered live on Zoom. Don’t miss this opportunity and register now to make sure you book your place and take part in knowledge exchange and discussions!  \n\n\n\n\nRegister for the live webinar\n\n\n\n\nLanguage\n\n\n\nThe session will be held in English with translated auto-captions into many languages (offered by Zoom platform). \n\n\n\nFind out more about the speakers:\n\n\n\nProf. Bart Van Wijmeersch\n\n\n\nChair and moderator \n\n\n\nNeurologist and Medical Director at the Rehabilitation & MS Center in Pelt\, Belgium\, and Associate Professor at Hasselt University. \n\n\n\nDr Serena Borrelli\n\n\n\nSpeaker \n\n\n\nNeurologist and Medical Doctor at Univertsité Libre de Bruxelles\, Belgium \n\n\n\nProf. Jérôme de Sèze\n\n\n\nSpeaker \n\n\n\nNeurologist at Strasbourg University Hospitals and Head of the MS Expert Centre / CRC SEP in France. \n\n\n\nPiet Eelen\, RN\, MSc\n\n\n\nSpeaker \n\n\n\nClinical Nurse Specialist in Multiple Sclerosis at the National MS Center in Melsbroek\, Belgium. \n\n\n\nFunding\n\n\n\nThis webinar was organized with the financial support of Sandoz. \n\n\n\nSandoz has not been involved in the elaboration of the presentations. URL:https://paradigms.foundation/event/live-webinar-a-biosimilar-in-multiple-sclerosis-care-in-belgium-evidence-confidence-and-implementation/ ATTACH;FMTTYPE=image/jpeg:https://paradigms.foundation/wp-content/uploads/2026/08/paradigms-foundation-webinar-biosimilars-in-belgium-002.jpg END:VEVENT BEGIN:VEVENT DTSTART;TZID=Europe/Paris:20261127T123000 DTEND;TZID=Europe/Paris:20261127T190000 DTSTAMP:20261021T134302Z CREATED:20260714T094238Z LAST-MODIFIED:20261021T134302Z UID:14567-1795782600-1795806000@paradigms.foundation SUMMARY:Paradigms Regional MS Symposium DESCRIPTION:Co-organized by the Hungarian Neuroimmunology Society and by ParadigMS Foundation\, the Symposium is specifically designed to address the clinical and educational needs of the region. \n\n\n\nThe meeting will take place in Szeged\, Hungary.\n\n\n\n\n\n\n\n\nRegister to join the IN-PERSON meeting\n\n\n\n\nMeeting details\n\n\n\nDate: Friday\, 27 November 2026Time: 12:30-19:05Location: ART Hotel\, Szeged\, 6720 Somogyi u. 16m\, Hungary \n\n\n\nOrganised by: Paradig:S and the Hungarian Neuroimmunology Society \n\n\n\nAdvances in the management of neuroimmunological diseases continue to raise new clinical questions. This regional symposium will provide an interactive forum where experts discuss real-world therapeutic challenges in Multiple Sclerosis (MS)\, Neuromyelitis Optica Spectrum Disorder (NMOSD) and Myelin Oligodendrocyte Glycoprotein Antibody Disease (MOGAD). Through case presentations\, panel debates and evidence-based lectures\, participants will explore practical approaches to diagnosis\, treatment optimisation and regional clinical practice. \n\n\n\nVenue\n\n\n\nART HotelSomogyi u. 16\, 6720 Szeged\, Hungary \n\n\n\n\n\n\n\nScientific committee\n\n\n\n\nCecilia Rajda\n\n\n\nMelinda Magyari\n\n\n\nGregor Brecl Jakob\n\n\n\nMario Habek\n\n\n\nRodica Balasa\n\n\n\nJelena Drulovic \n\n\n\n\nProgramme overview\n\n\n\nParadigMS Regional MS Symposium_Szeged 2026 – Programme 0210Download\n\n\n\n\n\n\n\nWhy attend?\n\n\n\nThis regional symposium offers an opportunity to engage with leading experts on current therapeutic challenges in Multiple Sclerosis (MS)\, Neuromyelitis Optica Spectrum Disorder (NMOSD) and Myelin Oligodendrocyte Glycoprotein Antibody Disease (MOGAD). Through debate-style sessions\, case-based learning and expert presentations\, participants will gain practical insights into treatment optimisation\, evolving diagnostic criteria\, long-term risk mitigation and region-specific approaches to patient management. \n\n\n\nOrganised by\n\n\n\n\nHungarian Neuroimmunology Society\n\n\n\nParadigms Foundation\n\n\n\n\n \n \n \n \n Hungarian Neuroimmunology Society\n \n \n \n Paradigms Foundation\n \n \n \n \n \n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n\n \n \n \n \n\n\nOur Partners \n\n\n\n \n \n \n \n Amgen\n \n \n \n AstraZeneca\n \n \n \n Merck\n \n \n \n Neuraxpharm\n \n \n \n Novartis\n \n \n \n QPharma \n \n \n \n \n \n \n \n Richter Gedeon\n \n \n \n Roche \n \n \n \n Sandoz\n \n \n \n Teva URL:https://paradigms.foundation/event/paradigms-regional-ms-symposium-2/ ATTACH;FMTTYPE=image/jpeg:https://paradigms.foundation/wp-content/uploads/2026/07/PMS-PROD-Regional-Symposium-2026-banner-1080x655px-02.jpg END:VEVENT BEGIN:VEVENT DTSTART;TZID=Europe/Paris:20261203T134500 DTEND;TZID=Europe/Paris:20261203T144500 DTSTAMP:20260922T100812Z CREATED:20260922T100423Z LAST-MODIFIED:20260922T100812Z UID:14932-1796305500-1796309100@paradigms.foundation SUMMARY:Paradigms pre-MENACTRIMS Symposium 2026 DESCRIPTION:Intercontinental Festival City\, Dubai\, United Arab Emirates \n\n\n\nAdvancing Multiple Sclerosis Care Across the Middle East and North Africa\n\n\n\nMENACTRIMS\, the Middle East North Africa Committee for Treatment and Research in Multiple Sclerosis\, is a regional scientific organisation dedicated to advancing knowledge\, research\, education and clinical care in multiple sclerosis (MS) and related neuroimmunological disorders across the Middle East and North Africa. \n\n\n\nMENACTRIMS brings together neurologists\, researchers\, healthcare professionals and experts from across the region and internationally\, creating a platform for scientific exchange\, collaboration and education. \n\n\n\nThrough its scientific and educational activities\, MENACTRIMS aims to support healthcare professionals in navigating a rapidly evolving MS landscape and translating advances in research\, diagnosis\, monitoring and treatment into meaningful improvements in clinical practice. \n\n\n\nParadigMS Pre-MENACTRIMS Symposium\n\n\n\nFrom Biomarkers to Better Decisions in Multiple Sclerosis\n\n\n\nHeld in conjunction with MENACTRIMS\, the ParadigMS Pre-MENACTRIMS Symposium is a focused scientific and educational meeting bringing together experts in multiple sclerosis to explore how emerging tools and biomarkers can support more personalised approaches to MS management. \n\n\n\nAs the MS treatment landscape becomes increasingly complex\, clinicians have access to a growing range of information beyond conventional clinical assessment. Advanced imaging\, fluid biomarkers and digital technologies offer new possibilities for detecting disease activity\, evaluating treatment response and identifying patients who may be at greater risk of progression. \n\n\n\nThe symposium will examine how these developments can move from scientific promise towards meaningful application in everyday clinical practice. \n\n\n\nKey Takeaways\n\n\n\n\nHow technological\, imaging and fluid biomarkers may contribute to more personalised MS treatment decisions.\n\n\n\nWhich biomarker signals may help identify subclinical disease activity\, treatment response and progression risk.\n\n\n\nThe role of imaging biomarkers in monitoring inflammatory activity\, neurodegeneration and smouldering disease.\n\n\n\nHow serum neurofilament light chain and other fluid biomarkers may be interpreted in clinical practice.\n\n\n\nHow digital and wearable technologies may complement clinic-based assessment by capturing real-world function over time.\n\n\n\nThe key limitations\, confounding factors and standardisation issues affecting biomarker interpretation.\n\n\n\nHow biomarker information can be integrated with clinical judgement\, MRI findings\, patient characteristics and treatment goals.\n\n\n\nWhich biomarkers are closest to routine clinical implementation and which remain primarily investigational.\n\n\n\nHow biomarker strategies may be adapted to different healthcare systems and levels of resource availability.\n\n\n\n\nWith thanks to our sponsor\, who supports this event without any involvement in the elaboration of the presentations. URL:https://paradigms.foundation/event/paradigms-pre-menactrims-symposium-2026/ ATTACH;FMTTYPE=image/png:https://paradigms.foundation/wp-content/uploads/2026/09/Banner-MENACTRIMS-2026.png END:VEVENT BEGIN:VEVENT DTSTART;TZID=Europe/Paris:20261221T170000 DTEND;TZID=Europe/Paris:20261221T180000 DTSTAMP:20260922T101743Z CREATED:20260902T100219Z LAST-MODIFIED:20260922T101743Z UID:14751-1797872400-1797876000@paradigms.foundation SUMMARY:Live Webinar on the new therapies in Myasthenia Gravis DESCRIPTION:Live webinar | Monday 21 December 2026 | 17:00–18:00 CET \n\n\n\nJoin this live ParadigMS webinar for an expert-led discussion on new and emerging therapies in myasthenia gravis\, with a focus on their relevance for clinical practice. \n\n\n\nDuring this one-hour session\, Andrew Chan\, Maura Pugliatti and Celia Oreja-Guevara will review current developments and discuss how advances in treatment may influence therapeutic decision-making. \n\n\n\nThe session will bring together leading experts to discuss current clinical considerations and provide practical insights relevant to neurologists and healthcare professionals involved in MS care. \n\n\n\nRegister to join the live webinar and hear perspectives from leading neurology experts. \n\n\n\nKey Highlights\n\n\n\nThe session will provide an expert overview of the changing treatment landscape in myasthenia gravis and its implications for clinical practice. Participants will have the opportunity to: \n\n\n\n\nExplore recent developments in therapies for myasthenia gravis.\n\n\n\nReview the evolving therapeutic landscape.\n\n\n\nConsider the clinical relevance of new treatment options.\n\n\n\nHear expert perspectives on treatment decision-making.\n\n\n\nJoin the discussion during the live session.\n\n\n\n\nMore information & Learning Objectives to come soon\n\n\n\nRegister\n\n\n\nThis session will be delivered live on Zoom. Don’t miss this opportunity and register now to make sure you book your place and take part in knowledge exchange and discussions!  \n\n\n\nLanguage\n\n\n\nThe session will be held in English with translated auto-captions into many languages (offered by Zoom platform). \n\n\n\nWho should attend?\n\n\n\n\nNeurologists and paediatric neurologists with an interest in Multiple Sclerosis\n\n\n\nMS specialists and neurologists in training\n\n\n\nNurses and other healthcare professionals involved in MS care\n\n\n\nHealthcare professionals involved in the diagnosis or management of paediatric demyelinating disorders\n\n\n\n\nQuestions and comments\n\n\n\nShould you have specific questions\, you would like to see discussed\, please share them with learning@paradigms.foundation now\, so the speakers could relate to them in their presentations.  \n\n\n\nYou will also have the opportunity to ask questions in person and participate in discussion during the webinar and the Q&A session. \n\n\n\nTechnology used\n\n\n\nThe webinar takes place via Zoom\, you will receive connection details upon registration. \n\n\n\nDate and time\n\n\n\nDate: Monday 21 December 2026Time: 17:00-18:00 CETFormat: Live online webinarDuration: 60 minutes \n\n\n\nSpeakers\n\n\n\nFind out more about the speakers: \n\n\n\n\n\n\n\nCelia Oreja-Guevara \n\n\n\nVice Chair of Neurology and Head of Multiple Sclerosis Center at the University Hospital San Carlos\, Madrid \n\n\n\n\n\n\n\nAndrew Chan \n\n\n\nHead of the Medical Division Neuro at the Bern University Hospital \n\n\n\n\n\n\n\nMaura Pugliatti \n\n\n\nProfessor of Neurology at the University of Ferrara \n\n\n\nFunding\n\n\n\nThis webinar is funded with ParadigMS own funds. No other sponsors have been invited to support this webinar. URL:https://paradigms.foundation/event/new-therapies-in-myasthenia-gravis/ ATTACH;FMTTYPE=image/png:https://paradigms.foundation/wp-content/uploads/2026/09/New-therapies-in-MG.png END:VEVENT END:VCALENDAR